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Evaluation of microarray-based DNA methylation
measurement using technical replicates: the
Atherosclerosis Risk In Communities (ARIC) Study
Maitreyee Bose1, Chong Wu1, James S Pankow2, Ellen W Demerath2, Jan Bressler3, Myriam Fornage3,
Megan L Grove3, Thomas H Mosley4, Chindo Hicks4, Kari North5, Wen Hong Kao6, Yu Zhang7, Eric Boerwinkle3
and Weihua Guan1*
Abstract
Background: DNA methylation is a widely studied epigenetic phenomenon; alterations in methylation patterns
influence human phenotypes and risk of disease. As part of the Atherosclerosis Risk in Communities (ARIC) study,
the Illumina Infinium HumanMethylation450 (HM450) BeadChip was used to measure DNA methylation in
peripheral blood obtained from ~3000 African American study participants. Over 480,000 cytosine-guanine (CpG)
dinucleotide sites were surveyed on the HM450 BeadChip. To evaluate the impact of technical variation, 265
technical replicates from 130 participants were included in the study.
Results: For each CpG site, we calculated the intraclass correlation coefficient (ICC) to compare variation of
methylation levels within- and between-replicate pairs, ranging between 0 and 1. We modeled the distribution of
ICC as a mixture of censored or truncated normal and normal distributions using an EM algorithm. The CpG sites
were clustered into low- and high-reliability groups, according to the calculated posterior probabilities. We also
demonstrated the performance of this clustering when applied to a study of association between methylation levels
and smoking status of individuals. For the CpG sites showing genome-wide significant association with smoking
status, most (~96%) were seen from sites in the high reliability cluster.
Conclusions: We suggest that CpG sites with low ICC may be excluded from subsequent association analyses, or
extra caution needs to be taken for associations at such sites.
Keywords: DNA methylation, Infinium 450 K chip, Technical error, Intraclass correlation, Normal mixture models
Background
DNA methylation is one of the most commonly occurring
epigenetic phenomena in the human genome. It is one
of the major regulators of gene transcription and
plays a vital role in many cellular processes. In the last
decade, numerous studies have shown that abnormal
methylation patterns are linked to phenotypic differences
and development of disease [1-6].
Recent technological advances have provided multiple
platforms for systematically interrogating DNA methylation
variation across the genome [7]. Among them, the Illumina
HumanMethylation450 BeadChip (HM450) (Illumina, Inc.)
is a new-generation array constituting a major extension of
the previous Infinium HumanMethylation27 BeadChip
(HM27) (Illumina, Inc.) and can be used to assess the
methylation condition of more than 480,000 cytosines
distributed over the entire genome. Sandoval et al. [8]
validated the HM450 chip by showing that methylation
patterns measured in colorectal cancer cell lines and
normal mucosa were consistent with those found in
bisulfite genomic sequencing. Other recent studies have
extensively evaluated data generated from this chip and
developed data processing and analysis pipelines [9-11].
Similar to other microarray experiments (e.g. RNA
expression), it is important to evaluate the impact of
technical variation in the measurement. A well-known
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source of bias for epigenome-wide association studies
(EWASs) of DNA methylation is the so-called “batch
effect”, which is largely caused by technical differences from
one chip to the next. Although many statistical methods
have been proposed to correct for batch effects [12-17], no
approach has been generally accepted. Alternatively, it will
be useful to consider statistical measures that can quantify
the extent to which the measured methylation level at a
specific CpG site is affected by technical errors. For CpG
sites with large inter-individual variation, it may be reason-
able to assume that technical differences will have relatively
low impact at these sites. However, the HM450 chip
contains a large number of CpG sites with little inter-
individual variation in methylation levels, for which it is
critical to consider additional statistics to evaluate the
impact of technical errors.
In experiments, technical replicates are often included
which can be used to evaluate the consistency of measure-
ment. Meng et al. [18] suggested using technical replicates
to identify and exclude “non-variable” CpG sites, at which
the technical “noise” outperforms true biological variation.
Their data came from the Illumina GoldenGate methyla-
tion array and consisted of 311 samples assayed at 1,505
sites. However, no comprehensive work has been done for
the HM450 chip.
In the Atherosclerosis Risk in Communities (ARIC)
study, the HM450 chip was used for genome wide profiling
of DNA methylation in 2,873 African-American individuals
assayed at 485,577 CpG sites, with 130 replicate pairs
or triplets included. We evaluated the consistency of
methylation measurement at each CpG site based on the
intraclass correlation coefficient (ICC), which compares
the within- and between-replicate variations. We next
modeled the ICC values using a mixture model approach
to classify CpG sites on the HM450 chip into high and
low reliability clusters. We demonstrated the relationship
of this classification to the results of an association study
between methylation level and smoking status of ARIC
study participants.
The aim of this work was to apply a statistical procedure
to identify CpG sites which give consistent values for
methylation levels in DNA extracted from peripheral
blood using the HM450 chip (or a similar methylation
profiling array), thereby providing insight into the
performance of this chip across CpG sites. We hope that
our results will facilitate subsequent EWAS analyses.
Results
Based on the ICC, we quantified the reliability of methyla-
tion measurements on the HM450 chip using technical
replicates included in the analysis of DNA methylation in
ARIC study participants. The CpG sites were then classified
into low and high reliability groups by modeling the
distribution of the ICC. We further demonstrated the
relationship of measurement reliability to the associations
between methylation and smoking status in the ARIC study.
Distribution of ICC
Using the 265 technical replicates available in the ARIC
methylation data, we calculated the ICC value for each
CpG site assayed on the HM450 chip. After excluding
sites with low pass rate, 473,788 CpG sites were analyzed.
The distribution of ICC is shown in Figure 1. The median
ICC value was 0.30. We observed one cluster of sites with
relatively high ICC values (mode ~ 0.75), one cluster with
relatively low ICC values (model ~ 0.10), and an additional
cluster of sites with ICC of 0 (n = 36,017). This empirical
distribution supported the truncated/censored normal
mixture model we assumed.
We further investigated how the ICC values change
with the variation (standard deviation, SD) of methyla-
tion levels. It is reasonable to assume that when the SD
is large, the relative impact of technical error becomes
small and methylation measures for technical replicates
will in general be consistent. Using a locally weighted
scatterplot smoothing (LOWESS) approach, we observed
a positive correlation between ICC and variation of
methylation (Figure 2). In practice, an EWAS can apply
a filter based on methylation variation to focus on CpG
sites with large variation, e.g., SD > 0.1 [19]. In our results,
among CpG sites with SD of 0.1 or above (n = 21,593),
78% had ICC > 0.80, and 95% had ICC > 0.37 (belonging
to the high reliability cluster; see below). However, these
sites accounted for only 4% of the CpG sites surveyed
by the HM450 chip. It is therefore important to assess
measurement reliability on the CpG sites with low or
moderate variation in methylation levels.
We examined the distribution of ICC values by the
two types of Infinium probes (Figure 3). Compared to
the Infinium II probes, a larger proportion of Infinium I
Figure 1 Distribution of intraclass correlation coefficients (ICC)
in the ARIC methylation data.
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probes showed smaller ICC values and less consistency
between technical replicates. Specifically, there are
31.7% Infinium I probes with ICC > 0.4, while 46.2%
of Infinium II probes have ICC > 0.4. Similar comparison
was done for CpG sites’ relation to CpG islands (Figure 4).
The Infinium I probes have higher proportions in CpG
islands than the Infinium II probes [20], and we observed
less sites in CpG islands with high ICC compared to those
not in CpG islands.
Chen et al. [21] reported a list of cross-reactive probes
(~6%) on the HM450 chip that can co-hybridize to alternate
sequences on the genome. We observed enrichment for
these probes with low ICC values (Figure 5), suggesting that
cross-reactivity may explain the low reliability at some CpG
sites. In addition, we examined the distribution of ICC for
CpG sites within 50 bp of SNPs [22], but found no signifi-
cant difference from rest of the CpG sites (Figure 5).
Classification of CpG sites using mixture models
To classify the CpG sites based on the consistency of
methylation measures between technical replicates, we
used a mixture model approach to the observed ICC
values. We first fit a censored normal mixture model,
which assumes a high reliability cluster of CpG sites (ICC
following a normal distribution) and a low reliability
cluster (ICC following a censored normal distribution). In
addition, we fit a truncated normal mixture model to the
non-zero ICC values, to allow flexibility in modeling
the cluster of ICC equal to 0. Estimates of the mixing
proportion of the high reliability component, means and
standard deviations of the two normal distributions are
given in Table 1.
The observed and fitted distributions of ICC values
for the two models are shown in Figures 6 and 7.
The maximized log likelihood value was compared for
Figure 2 Relationship between ICC and standard deviation of
methylation level. The dashed line is the fitted curve using a local
regression (LOWESS) approach.
Figure 3 Distribution of ICC values for the Infinium I and II probes.
Figure 4 Distribution of ICC values and their relation to
CpG islands.
Figure 5 Distribution of ICC for all CpG sites, CpG sites within
50 bp of SNPs, and cross-reactive probes reported by
Chen et al. [21].
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the two mixture models (Table 1). The truncated normal
mixture model using sample proportions to estimate the
relative size of the cluster for ICC = 0 had a higher
maximized log likelihood than that of the censored
normal mixture model. In the following discussion,
we grouped the CpG sites with ICC = 0 as a separate
cluster (“zero-ICC”), and classified the sites with non-
zero ICC values into low reliability and high reliability
clusters based on the posterior probability π from the
fitted truncated normal mixture model. To maximize
the size of the high reliability cluster, we chose a rather
low cutoff value of 0.01 for π (see Discussion), which
corresponds to an ICC value of 0.37. The numbers of
CpG sites classified into each of the three clusters
were: 36,017 (ICC = 0), 228,231 (low reliability cluster),
and 209,540 (high reliability cluster).
Data application: association with smoking status
Next, we investigated how association patterns between
phenotypes and methylation levels vary across different
reliability clusters using smoking status from the ARIC
Study as an illustrative example. Complete information
on methylation levels, smoking status, and covariates
was available for 2,835 African American participants.
The average age was 56.7 years (standard deviation, SD,
5.9 years), 63.4% were female, and 25.6% were current
smokers. 874 CpG methylation sites displayed genome
wide significant association (p < 10−7), with current
smoking status, or 723 CpG sites after excluding those
with at least one common SNP within 50 base pairs.
Among the 723 associated sites, only 31 were from the
low reliability cluster, and none from the zero-ICC cluster.
We further investigated distributions of the smoking-
associated CpG sites in the low and high reliability clusters,
and compared to the distribution of ICC values in each
cluster (Figures 8 and 9). In both clusters the number of
associated sites increases with increase in ICC values. In
the low reliability cluster, most of the associated CpG sites
Table 1 Fitted models for ICC distribution
Censored normal
mixture
Truncated normal
mixture
p 0.55 0.67
μ1 0.15 0.04
μ2 0.67 0.72
σ1 0.14 0.28
σ2 0.14 0.11
Maximized log likelihood −86500 −80230
Figure 6 Observed and fitted distributions of ICC values using
the censored normal mixture model.
Figure 7 Observed and fitted distributions of ICC values using
the truncated normal mixture model (for non-zero ICC).
Figure 8 Distribution of ICC values of smoking-associated CpG
sites belonging to the low reliability cluster.
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had ICC > 0.2, while a high density of low ICC (<0.2) values
was observed in this cluster. In the high reliability cluster,
the distribution of associated sites was more proportional
to the distribution of ICC. The relationship between
association p-values and ICC at all CpG sites is shown in
Additional file 1: Figure S1.
Discussion
Recent technological advances have provided high-
throughput array for systematically interrogating DNA
methylation across the genome. This allows investigators
to evaluate regions of the genome in which variation in
DNA methylation may influence gene expression and
ultimately disease risk. One of the potential problems
that could threaten the validity of methylation-phenotype
association results is the variability of technical measure-
ments (e.g., batch effects). Here we used technical replicates
to assess reliability of methylation measurement on CpG
sites interrogated by the HM450 chip. Using a mixture
model approach, we classified CpG sites into low and high
reliability groups. The ICC value can serve as a measure to
quantify the impact of technical errors, especially batch
effects. In addition, CpG sites with low reliability could
be excluded in subsequent analyses to improve the
power of EWASs by reducing the burden of multiple
hypothesis tests.
In our analysis of 265 technical replicates available as
part of the ARIC methylation data, we classified CpG
sites on the HM450 chip by a mixture of truncated
normal and normal distributions, with ~44% sites in
the cluster of high reliability. For CpG sites with high
ICC values, the variation between independent biological
samples is relatively large compared to the variation due
to technical error. We expect statistical tests performed
for the sites with high ICC will have more power to detect
association between methylation level and phenotype of
interest than for the sites with low ICC. In the follow-up
EWAS of smoking status, we showed that a majority
(96%) of genome-wide significant associations are from
the high reliability cluster, even though only 44% of all
sites were in this cluster.
The ICC provides a measure of reliability for the
methylation measurement. In EWASs, it is well known
that batch effects can threaten the validity of association
results [14]. Commonly used methods for batch effects
correction include empirical Bayes methods [17], surrogate
variables [15,16], and linear mixed-effects (LMM) models.
However, it is difficult to completely control or remove
batch effects in association tests. Alternatively, we can use
ICC to quantify to what extent the batch effects can affect
the methylation measures. The probes for CpG sites with
low ICC are expected to be more vulnerable to technical
variability including batch effects. Similar to the ICC for
replicates, we calculated ICC for chip effects (ICCchip),
which is the proportion of variation in measured
methylation levels due to chip difference in the experiment.
Additional file 1: Figure S2 shows that when ICCchip is
close to 1, most of the variation in methylation measures is
due to technical “errors”. Reliability of methylation
measures is therefore low at these CpG sites, with ICC for
replicates close to 0. On the other hand, when ICC for
replicates is close to 1, technical variability has minimal
contribution to the methylation measures, and little batch
effects are observed (ICCchip ≈ 0).
In addition to the EWAS of smoking status using
LMM, we performed the EWAS using a linear regression
model without adjusting for chip and chip position
(results not shown). There were 1,783 CpG sites signifi-
cantly associated with smoking status, after excluding sites
with low pass rate or with at least one common SNP
within 50 base pairs. Among these sites, there was no
site in the zero-ICC cluster, 253 sites from the low
reliability cluster, and 1,530 sites from the high reliability
cluster. All except 9 sites identified by the LMM were also
genome-wide significant in this model. The number of
significant sites without adjustment for chip and chip
position was approximately 2.5-fold higher than we
observed in the EWAS with those adjustments. We
hypothesize that some of the additional associations
are false positives due to technical errors. We also
compared our results to published EWASs of smoking
studies [23-27], which were carried out in individuals
of European and African ancestry. We were able to
validate ~80% of the reported signals with genome-
wide significance. Of these, 32 sites were found within the
body of the aryl-hydrocarbon receptor repressor (AHRR)
gene, with a 15% decrease in the mean methylation
level of cp05575921 in current smokers compared to
non-smokers (p = 6.2 × 10−196) as previously shown in
the other studies.
Figure 9 Distribution ICC values of smoking-associated CpG
sites belonging to the high reliability cluster.
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The ICC value is determined by two variance compo-
nents, σ2b for variance between independent samples and
σ2w for variance within replicates of the same sample.
When sample characteristics (e.g., cell type composition,
sample ethnicity, or genetic variants) are controlled for, σ2b
becomes smaller which leads to smaller ICC than the
current estimates (in Additional file 1: Figure S3). When
batch effects are controlled for, both σ2b and σ
2
w can be
reduced and the ICC can increase or decrease at different
CpG sites (in Additional file 1: Figure S4).
The empirical distribution of C we observed is similar to
that of Meng et al. [15], in which an earlier version of the
Illumina GoldenGate array having 1,505 CpG sites was
used. In their analysis, Pearson product–moment correl-
ation was primarily used between replicate pairs, although
ICC was also introduced. Our analysis updates the informa-
tion for the HM450 chip, and focuses on ICC which allows
more than two replicates per biological sample.
Meng et al. observed that, compared to CpG sites not in
CpG islands, a higher proportion of sites in CpG islands
showed low inter-individual variation in methylation levels
relative to within-individual variation (“non-variable”),
consistent with a previous finding by Bock et al. [28]. Our
results further confirmed this observation. In contrast,
Dedeurwaerder et al. [10] studied technical replicates
of a human colon cancer cell line and showed that the
probe-wise variation of methylation levels were greater for
Infinium II probes than those for Infinium I probes. How-
ever, their findings were limited to within-individual
variation, with no comparison to inter-individual vari-
ation. In addition, given the small number of replicates,
the impact of batch effects was minimal in their study.
Therefore the results were not directly comparable.
From the distribution of ICC values we noted that the
distribution of high ICC component is slightly left
skewed, with few CpG sites having ICC close to 1. Because
of the normal distribution assumption for this component
in the mixture model, this skewness may lead to an
underestimate for the corresponding variance parameter
σ22
 
and under-fit the distribution of ICC in the middle
(0.2-0.5), in both of the truncated and censored normal
mixture models. The direct consequence is that CpG sites
with moderate ICC values will have a small posterior
probability of being in the high reliability cluster. As
a possible remedy, we considered three-component
mixture models, with an additional normal distribution
component to model the moderate ICC values. However,
the model fit was poorer than the 2-component models
(results not shown).
To classify the CpG sites into different reliability groups,
Meng et al. [18] chose a cutoff of 0.5 for the posterior
probability and suggested to exclude the “non-variable”
sites in the low reliability group. In contrast, we set a
rather small cutoff of 0.01 to include more sites with
moderate ICC into the high reliability cluster, given the
discussion above. In the ARIC study, the low reliability
cluster contributes only ~4% of significant associations in
the EWAS of smoking status, with only two associated
sites having ICC < 0.1. We believe that validation using
other approaches is especially important for sites with
low ICC, for example, bisulphite pyrosequencing and
replication in an external validation cohort. In this
specific example, restricting analysis to CpG sites in
the high reliability cluster would result in the loss of
only a few significant association signals and could
improve the power of EWAS by reducing the number
of hypothesis tests by more than a half. To demonstrate,
we calculated the statistical power at different effect
sizes (%variance explained), based on a sample size of
2,500 and genome-wide significance level determined using
Bonferroni correction. We assume 50% CpG sites will be
excluded due to low ICC. We observe power increase
of ~5% under this setting (in Additional file 1: Figure S5).
For other studies, investigators may decide their own cutoff
for the ICC. Even if all CpG sites on the chip are to be
included in the association analysis, the ICC can still serve
as a measure of how likely the association results are to be
affected by technical errors.
Here, we aimed to describe the distribution of ICC
using a statistical approach. Our results clearly approximate
the observed distribution. However, it is unknown
what biological or chemical factors explain the difference
in performance of the corresponding probes on the chip
between the low (including zero-ICC) and high reliability
clusters. It is also unknown whether our results can be
generalized to other populations or other types of tissues.
The methylation profiling in ARIC samples are from white
blood cells, which is a mixture of multiple cell types, and
the participants are African Americans. It has been shown
that both cell type composition [29] and sample ethnicity
[22] can heavily influence DNA methylation pattern. It
is unknown whether our results will still hold when a
purified cell type, e.g., monocytes or neutrophils, or differ-
ent tissue is used, or when samples from different ethnic
groups are included. As an example, Etcheverry et al. [19]
carried out an EWAS to identify CpG sites differentially
methylated between glioblastoma and control samples
using brain tissues. Among the 616 CpG sites identi-
fied, 584 are interrogated on the HM450 BeadChip.
We examined the ICC values for these 584 sites in
our data, and found 486 sites to belong to the high
reliability group (ICC > 0.37), 88 to belong to the low
reliability group, and 10 to belong to the zero-ICC
group. Enrichment of significant associations in the
high-ICC group in that study suggests that our results
may have reasonable generality.
In addition, we used the “raw” methylation measures
produced by the GenomeStudio software with minimal
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normalization. Other normalization procedures or use of
M-values [30] instead of β-values may result in different
ICC values. However, the same analytical approach used
here can be applied in other studies, if technical replicates
are included.
Another limitation of the study is that we did not take
into account the estimation uncertainty when estimating
the ICC, which can lead to different confidence intervals
for this reliability measure. We will consider a weighted
estimation approach in future studies, and re-classify the
CpG sites on the HM450 chip.
Conclusions
We examined the reliability of methylation measurements
using the latest HM450 chip, and demonstrated that
the CpG sites assayed on this array can be potentially
classified according to different levels of reliability. We
also evaluated the impact of measurement reliability on
results of EWAS. The biological differences between the
clusters of CpG sites need to be further investigated. The
estimated ICC values for all CpG sites on the HM450 chip
are available in Additional file 2. We hope that our results
can provide additional guidance on inclusion/exclusion of
CpG sites for future EWASs using the HM450 chip, and
our analysis approach can be generalized to other types of
methylation arrays.
Methods
To evaluate the reliability of methylation measurement
assayed on the HM450 chip, an intraclass correlation
coefficient (ICC) can be calculated for each CpG site
using the technical replicates. We aim to classify the CpG
sites into multiple reliability groups, by modeling the
distribution of ICC values using a mixture distribution.
The ARIC methylation data
The Atherosclerosis Risk in Communities (ARIC) Study
is a prospective cohort study of cardiovascular disease
risk in four U.S. communities [31]. Between 1987 and 1989,
7,082 men and 8,710 women aged 45–64 years were
recruited from Forsyth County, North Carolina; Jackson,
Mississippi (African Americans only); suburban Minneapolis,
Minnesota; and Washington County, Maryland. The
ARIC Study protocol was approved by the institutional
review board of each participating university. Participants
underwent a baseline clinical examination (Visit 1) and
four subsequent follow-up clinical exams (Visits 2–5).
Written informed consent was obtained for each clinic
exam, including that for genetic studies.
Genomic DNA was extracted from peripheral blood
leukocyte samples using the Gentra Puregene Blood Kit
(Qiagen) according to the manufacturer’s instructions
(www.qiagen.com). Bisulphite conversion of 1 ug genomic
DNA was performed using the EZ-96 DNA Methylation
Kit (Deep Well Format) (Zymo Research) according to
the manufacturer’s instructions (www.zymoresearch.com).
Bisulphite conversion efficiency was determined by PCR
amplification of the converted DNA before proceeding
with methylation analyses on the Illumina platform using
Zymo Research’s Universal Methylated Human DNA
Standard and Control Primers.
Bisulphite-converted DNA from 2,905 African American
participants at Visit 2 (1990–92; n = 2,504) or Visit 3
(1993–95; n = 441) were measured for methylation status
using the HM450 chip. The degree of methylation is
determined using Illumina GenomeStudio 2011.1, Methy-
lation module 1.9.0 software. The methylation score for
each CpG was represented as a beta (β) value calculated
by dividing the fluorescence intensity of the methylated
allele by the sum of the intensities of the methylated
allele and unmethylated allele. β-values may take any
value between 0 (non-methylated) and 1 (completely
methylated). Background subtraction was conducted
with the GenomeStudio software using built-in negative
control bead types on the array. An average normalization
was also applied in GenomeStudio to minimize scanner-
to-scanner variation using ~90 normalization probe pairs
included on the array which target housekeeping regions
with no underlying CpG sites. These probes are used to
independently calculate normalization values in the green
and red channels so that all samples have the same
average intensity.
Individuals (n = 32) were excluded from analysis if a pass
rate for the DNA sample for the study participant was less
than 99% (probes with a detection p-value >0.01/all
probes on the array). Probes on the HM450 chip for
which the pass rate was less than 99% (sample with a
detection p-value >0.01 at probe/all samples) were
not analyzed (n = 11,789).
Technical replicates were included for 130 samples
(total n = 265 with 5 samples replicated 3 times), from
which the ICC values are calculated for all probes. All
except two of the replicate pairs were distributed on
different chips.
ICC estimation and modeling
At a specific CpG site, the methylation level can be
modeled using a random-effects ANOVA model:
yij ¼ μþ τj þ εij:
where yij is the measured methylation level for the ith
replicate of biological sample (replicate set) j, μ the overall
mean methylation at the site, τjeN 0; σ2b  a random effect
shared by all measures for sample j reflecting sample
characteristics, and εijeN 0; σ2w  a random noise term
including technical errors for multiple measures of
the same biological sample. τj and εij are assumed to be
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uncorrelated. Here σ2b presents variance between replicate
sets and σ2w represents variance within replicate sets. ICC
is calculated as:
ICC ¼ σ
2
b
σ2b þ σ2w
which takes values in [0,1] and measures the extent to
which the measurements in a replicate-set resemble each
other. An ICC of 1 indicates perfect measurement accuracy
at the CpG site, and 0 implies little variation between
independent samples but large measurement error
between technical replicates. Thus, we can classify sites
into clusters of varying degrees of reliability based on
ICC values.
The ICC value can serve as a measure for the impact
of batch effects on each probe. Consider a widely used
random-effects model for batch effects:
yij ¼ bl ijð Þ þ
X
p
Xjpβp þ eij
where l(ij) indexes the batch (chip) where replicate i of
sample j is located so bl(ij) is the corresponding batch effect,
and Xjp is the pth covariate (characteristic of biological
sample), such as age or sex, for sample j. Comparing this
model to the random-effects ANOVA model above, the
within replicate set variation σ2w is decomposed into
variances of batch-specific measurement error (bl(ij)) and
other technical error (eij), and
X
p
Xjpβp corresponds to
the between replicate set (biological sample) variation.
When the measure of methylation is vulnerable to batch
effects at a given CpG site, the variance of bl(ij) is large,
leading to small ICC.
Given that the ICC values are bounded in [0,1], especially
taking into account the lower bound of 0, we fit a censored
or truncated normal mixture models to the observed ICC
values. For the censored normal mixture model, we
assume that the CpG sites could be from two clusters: a
low reliability cluster with ICC censored at 0, and a high
reliability cluster with ICC distribution modeled by a
normal distribution:
f x; Θð Þ ¼ p Φ 0; μ1; σ21
 δi þ ϕ x; μ1; σ21 1−δi 
þ 1−pð Þϕ x; μ2; σ22
 
; pϵ 0; 1½ :
where δi = 1 for the censored observations (i.e., ICC = 0)
and 0 otherwise, p is the mixing proportion for the first
cluster, Θ ¼ p; μ1; σ21; μ2; σ22
 
the set of parameters,
and Φ(⋅) and ϕ(⋅) denote the cumulative and probability
distribution function of standard normal distribution,
respectively.
Alternatively, to allow excess 0 s in the distribution of
ICC, we separated CpG sites of ICC = 0 and modeled
non-zero ICC values using a truncated normal and a
normal mixture distribution:
f x; Θð Þ ¼ p ϕ x; μ1; σ
2
1
 
1−Φ 0; μ1; σ
2
1ð Þ
þ 1−pð Þϕ x; μ2; σ22
 
; p∈ 0; 1½ 
The parameters in the mixture models were estimated
using an Expectation-Maximization (EM) algorithm
[32,33]. For the purpose of comparison, we revised the
log-likelihood function to include the CpG sites with
ICC = 0:
logL Θ; xð Þ ¼ n0log p0ð Þ
þ
X
xϵICC≠0
log p1
ϕ x; μ1; σ
2
1
 
1−Φ 0; μ1; σ
2
1ð Þ
 
þ
X
xϵICC≠0
log p2ϕ x; μ2; σ
2
2
  
where p0 and n0 denote the sample proportion and num-
ber of sites with ICC = 0, respectively, and p1 = p(1 − p0)
and p2(1 − p)(1 − p0).
The two models were then compared using the
maximized log likelihood values. The CpG sites in-
terrogated by the HM450 chip can be classified
based on the corresponding posterior probabilities, π≡P
icc∈high reliability cluster icc; Θ^Þ , computed from either
of the two models.
Data application: association with smoking status
To demonstrate how association patterns between methyla-
tion levels at CpG sites and phenotypic characteristics of
individuals vary across the clustered sites, we investigated
the cross-sectional association of methylation levels and
smoking status in the ARIC Study. We fit a linear mixed-
effects (LMM) model of methylation on self-reported
smoking status (never/former smoker vs. current smoker),
adjusting for age, sex, body mass index, self-reported alco-
hol consumption (never/former vs. current drinker), the top
principal components of ancestry derived from genotype
data, visit number, field center, and chip row position as
fixed covariates. The values of the covariates were from the
specific visit at which the participant’s sample was obtained.
The batch (chip) effects were modeled as random effects.
Probes with at least one single nucleotide polymorphism
(SNP) within 50 base pairs of the CpG site and minor
allele frequency (MAF) > .05 based on all samples in
the 1000 Genomes project (http://www.1000genomes.org/)
were excluded [22]. We used p < 10−7 as genome-wide sig-
nificance based on a Bonferroni correction, and summarize
the number of significant associations by the low and high
reliability group, classified as above.
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